Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

65.02 USD -1.19 (-1.80%)
Official Closing Price Updated: 7:59 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Axsome Thera

< Previous 1 2 3 4 5 6 7 Next >
Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the... 
From GlobeNewswire News Releases
Edible Electronic Circuits Could be a Medical Revolution in the Waiting
From PR Newswire
Axsome Therapeutics to Participate in the Leerink Partners’ 2018 CNS Day
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot... 
From GlobeNewswire News Releases
Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will... 
From GlobeNewswire News Releases
Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot... 
From GlobeNewswire News Releases
Axsome Therapeutics to Present at 17th Annual Needham Healthcare Conference
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot... 
From GlobeNewswire News Releases
Technical Perspectives on Biotech Stocks -- Aimmune Therapeutics, Atara Biotherapeutics, AveXis, and Axsome Therapeutics
From PR Newswire
Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced... 
From GlobeNewswire News Releases
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial... 
From GlobeNewswire News Releases
Axsome Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018
Axsome to host conference call and webcast on Wednesday, March 7, 2018 at 8:00 AM Eastern Time 
From GlobeNewswire News Releases
Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced positive... 
From GlobeNewswire News Releases
Axsome Therapeutics to Present at 2018 BIO CEO & Investor Conference
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot... 
From GlobeNewswire News Releases
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that an... 
From GlobeNewswire News Releases
Axsome Therapeutics to Present at Biotech Showcase 2018
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot... 
From GlobeNewswire News Releases
Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, entered into a research... 
From GlobeNewswire News Releases
Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the closing... 
From GlobeNewswire News Releases
Axsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced At-the-Market
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it has... 
From GlobeNewswire News Releases
Axsome Therapeutics Announces AXS-07 for the Treatment of Migraine
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced its next... 
From GlobeNewswire News Releases
Axsome Therapeutics Reports Third Quarter 2017 Financial Results
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial... 
From GlobeNewswire News Releases
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot... 
From GlobeNewswire News Releases
Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017
Interim analysis results for both CREATE-1 and COAST-1 trials anticipated late December to early January 
From GlobeNewswire News Releases
Axsome Therapeutics Reports Second Quarter 2017 Financial Results
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial... 
From GlobeNewswire News Releases
Axsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced positive... 
From GlobeNewswire News Releases
Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient... 
From GlobeNewswire News Releases
Axsome Therapeutics Appoints John Golubieski as Chief Financial Officer
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the... 
From GlobeNewswire News Releases
Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the... 
From GlobeNewswire News Releases
Axsome Therapeutics Reports First Quarter 2017 Financial Results
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial... 
From GlobeNewswire News Releases
Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received Fast Track... 
From GlobeNewswire News Releases
Axsome Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the... 
From GlobeNewswire News Releases
Axsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.